Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avalglucosidase alfa versus alglucosidase alfa in treatment-naive late-onset Pompe disease
2016-000942-77Phase 3Unknown
- Sponsor
- Sanofi
- Start
- May 2016
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Pompe disease comparing Avalglucosidase alfa with Alglucosidase alfa (2 arms). Primary endpoint: Change from baseline in percent predicted forced vital capacity in upright position. Status: unknown.
02
Drugs
avalglucosidase alfaalglucosidase alfa
03
Conditions
Pompe disease
Beyond the preview
Go deeper on 2016-000942-77.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000942-77.